Home › Translarna Granted Orphan Drug Designation In The U.S. And Europe For The Treatment Of Mucopolysaccharidosis I
 

Keywords :   


Translarna Granted Orphan Drug Designation In The U.S. And Europe For The Treatment Of Mucopolysaccharidosis I

2014-12-29 01:43:03| drugdiscoveryonline Home Page

PTC Therapeutics, Inc. (Nasdaq: PTCT) today announced that both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have granted orphan-drug designation (ODD) to Translarna™ (ataluren) for the treatment of patients with Mucopolysaccharidosis I (MPS I)

Tags: of i europe treatment

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
07.11Hurricane Rafael Graphics
07.11Hurricane Rafael Forecast Discussion Number 16
07.11Hurricane Rafael Wind Speed Probabilities Number 16
07.11Hurricane Rafael Forecast Advisory Number 16
07.11Hurricane Rafael Public Advisory Number 16
07.11Summary for Hurricane Rafael (AT3/AL182024)
07.11Tropical Depression Fourteen-E Graphics
07.11Tropical Depression Fourteen-E Forecast Discussion Number 5
More »